Outcome of single agent generic gemcitabine in platinum- resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma
Single original gemcitabine is commonly used as salvage treatment in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma (PPA) with a satisfactory outcome. However, efficacy data fro this regimen are limited. We therefore conducted a retrospective study to...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
2014
|
Online Access: | http://www.ncbi.nlm.nih.gov/pubmed/22524817 http://cmuir.cmu.ac.th/handle/6653943832/3813 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
id |
th-cmuir.6653943832-3813 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-38132014-08-30T02:35:21Z Outcome of single agent generic gemcitabine in platinum- resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma Suprasert P. Cheewakriangkrai C. Manopunya M. Single original gemcitabine is commonly used as salvage treatment in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma (PPA) with a satisfactory outcome. However, efficacy data fro this regimen are limited. We therefore conducted a retrospective study to evaluate the outcome of patients who received single-agent generic gemcitabine (GEMITA) after development of clinical platinum resistance. The study period was between May 2008 and December 2010. Gemcitabine was administered intravenously in two different schedules: 1,000 mg/m2 on day 1,8, and 15 every 28 days; and on days 1 and 8 every 21 days with the same dosage. Administration was until disease progression was noted. The response rate was evaluated using the Gynecologic Cancer Intergroup (GCIG ) criteria while toxicity was evaluated according to WHO criteria. Sixty-six patients met the inclusion criteria in the study period. Two-thirds of them received gemcitabine as the second and third line regimen. The overall response rate was 12.1%. The median progression free survival and overall survival was 2 and 10 months, respectively. With the total 550 courses of chemotherapy,the patients developed grades 3 and 4 hematologic toxicity as follows: anemia, 1.5%; leukopenia, 13.7%; neutropenia, 27.3%; and thrombocytopenia, 3.0%. In conclusion, single agent generic gemcitabine revealed a modest efficacy in patients with platinum-resistant ovarian cancer, fallopian tube cancer and PPA without serious toxicity. 2014-08-30T02:35:21Z 2014-08-30T02:35:21Z 2012 Journal Article 1513-7368 22524817 http://www.ncbi.nlm.nih.gov/pubmed/22524817 http://cmuir.cmu.ac.th/handle/6653943832/3813 eng |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
country |
Thailand |
collection |
CMU Intellectual Repository |
language |
English |
description |
Single original gemcitabine is commonly used as salvage treatment in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma (PPA) with a satisfactory outcome. However, efficacy data fro this regimen are limited. We therefore conducted a retrospective study to evaluate the outcome of patients who received single-agent generic gemcitabine (GEMITA) after development of clinical platinum resistance. The study period was between May 2008 and December 2010. Gemcitabine was administered intravenously in two different schedules: 1,000 mg/m2 on day 1,8, and 15 every 28 days; and on days 1 and 8 every 21 days with the same dosage. Administration was until disease progression was noted. The response rate was evaluated using the Gynecologic Cancer Intergroup (GCIG ) criteria while toxicity was evaluated according to WHO criteria. Sixty-six patients met the inclusion criteria in the study period. Two-thirds of them received gemcitabine as the second and third line regimen. The overall response rate was 12.1%. The median progression free survival and overall survival was 2 and 10 months, respectively. With the total 550 courses of chemotherapy,the patients developed grades 3 and 4 hematologic toxicity as follows: anemia, 1.5%; leukopenia, 13.7%; neutropenia, 27.3%; and thrombocytopenia, 3.0%. In conclusion, single agent generic gemcitabine revealed a modest efficacy in patients with platinum-resistant ovarian cancer, fallopian tube cancer and PPA without serious toxicity. |
format |
Article |
author |
Suprasert P. Cheewakriangkrai C. Manopunya M. |
spellingShingle |
Suprasert P. Cheewakriangkrai C. Manopunya M. Outcome of single agent generic gemcitabine in platinum- resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma |
author_facet |
Suprasert P. Cheewakriangkrai C. Manopunya M. |
author_sort |
Suprasert P. |
title |
Outcome of single agent generic gemcitabine in platinum- resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma |
title_short |
Outcome of single agent generic gemcitabine in platinum- resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma |
title_full |
Outcome of single agent generic gemcitabine in platinum- resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma |
title_fullStr |
Outcome of single agent generic gemcitabine in platinum- resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma |
title_full_unstemmed |
Outcome of single agent generic gemcitabine in platinum- resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma |
title_sort |
outcome of single agent generic gemcitabine in platinum- resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma |
publishDate |
2014 |
url |
http://www.ncbi.nlm.nih.gov/pubmed/22524817 http://cmuir.cmu.ac.th/handle/6653943832/3813 |
_version_ |
1681420119388979200 |